Research programme: human papillomavirus vaccines - Redbiotec

Drug Profile

Research programme: human papillomavirus vaccines - Redbiotec

Alternative Names: RBT 201; RBT 202

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator Redbiotec
  • Class Papillomavirus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Human papillomavirus infections

Most Recent Events

  • 14 Feb 2017 No development reported - Preclinical for Human papillomavirus infections in Switzerland (Parenteral)
  • 17 Jan 2012 This programme is still in active development
  • 07 Oct 2008 Preclinical trials in Human papillomavirus infections in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top